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Introduction {#acn350942-sec-0005}
============

Neuronal ceroid lipofuscinosis type 2, also known as CLN2 disease, is a rare, autosomal recessive neurodegenerative condition in the neuronal ceroid lipofuscinoses (NCL) family of lysosomal storage disorders, affecting fewer than 1 in 100,000 live births in most studied populations.[1](#acn350942-bib-0001){ref-type="ref"}, [2](#acn350942-bib-0002){ref-type="ref"}, [3](#acn350942-bib-0003){ref-type="ref"} A number of sequence variants in *TPP1* cause a deficiency of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1) leading to intracellular accumulation of autofluorescent storage material, progressive neuronal dysfunction, brain atrophy, and retinal degeneration.[1](#acn350942-bib-0001){ref-type="ref"}, [2](#acn350942-bib-0002){ref-type="ref"}, [4](#acn350942-bib-0004){ref-type="ref"} In most cases, the onset of clinical signs occurs between 2 and 4 years of age. Typically, seizures are the first signs, followed by rapidly progressive language delay, motor dysfunction, ataxia, dementia, vision loss, and early death, usually by mid‐adolescence.[1](#acn350942-bib-0001){ref-type="ref"} In clinical trials, intracerebroventricular (ICV) infusions of the enzyme replacement therapy (ERT) cerliponase alfa (recombinant TPP1) led to over 80% attenuation in the rate of decline in motor and language scores of the CLN2 Clinical Rating Scale over a 96‐week treatment period.[5](#acn350942-bib-0005){ref-type="ref"} A canine model of CLN2 disease, the *TPP1‐*null Dachshund, also displays progressive neurological dysfunction and brain atrophy that can be ameliorated by infusions of recombinant human TPP1.[6](#acn350942-bib-0006){ref-type="ref"}

While the CLN2 Clinical Rating Scale is a standardized, quantitative scoring system, it does not include any measures of biochemical changes.[5](#acn350942-bib-0005){ref-type="ref"} Molecular markers of CLN2 disease pathophysiology would provide a quantitative measure of disease pathology to complement the CLN2 score, enabling clinicians to track physiological changes. Studies addressing gaps in NCL biomarkers have been limited by sample number and tissue accessibility,[7](#acn350942-bib-0007){ref-type="ref"} and often focused on biochemical consequences of the lysosomal defect. N‐acetylaspartate:creatinine ratios[8](#acn350942-bib-0008){ref-type="ref"} and brain and peripheral dolichol and lipid peroxidation products vary with disease state,[9](#acn350942-bib-0009){ref-type="ref"}, [10](#acn350942-bib-0010){ref-type="ref"}, [11](#acn350942-bib-0011){ref-type="ref"} as do urinary concentrations of mitochondrial ATP synthase subunit c, and plasma trimethyl‐L‐lysine and carnitine.[12](#acn350942-bib-0012){ref-type="ref"}, [13](#acn350942-bib-0013){ref-type="ref"} In cerebrospinal fluid (CSF) from CLN2 disease patients, proteomic profiling identified 34 proteins that were altered compared to controls,[14](#acn350942-bib-0014){ref-type="ref"} and an untargeted metabolite profiling study found 29 features that correlated with disease severity.[15](#acn350942-bib-0015){ref-type="ref"}

Neurofilament light (NF‐L, gene: *NEFL*), the most abundant of the four subunits comprising axonal and dendritic neurofilaments, acts in axonal growth and maintenance.[16](#acn350942-bib-0016){ref-type="ref"}, [17](#acn350942-bib-0017){ref-type="ref"} While *NEFL* gene expression is limited to nervous system tissues,[18](#acn350942-bib-0018){ref-type="ref"} NF‐L protein is detectable in CSF, serum, and plasma from healthy individuals, and is elevated in patients with neurological diseases including Alzheimer's disease, mild cognitive impairment, Guillain--Barré syndrome, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and HIV‐associated dementia.[16](#acn350942-bib-0016){ref-type="ref"}, [19](#acn350942-bib-0019){ref-type="ref"}, [20](#acn350942-bib-0020){ref-type="ref"}, [21](#acn350942-bib-0021){ref-type="ref"}, [22](#acn350942-bib-0022){ref-type="ref"} Elevated NF‐L has been linked to faster brain atrophy and disease progression in Alzheimer's disease, mild cognitive impairment, amyotrophic lateral sclerosis, Huntington's disease, frontotemporal dementia, and progressive supranuclear palsy.[16](#acn350942-bib-0016){ref-type="ref"}, [20](#acn350942-bib-0020){ref-type="ref"}, [22](#acn350942-bib-0022){ref-type="ref"}, [23](#acn350942-bib-0023){ref-type="ref"}, [24](#acn350942-bib-0024){ref-type="ref"}, [25](#acn350942-bib-0025){ref-type="ref"}, [26](#acn350942-bib-0026){ref-type="ref"}, [27](#acn350942-bib-0027){ref-type="ref"}, [28](#acn350942-bib-0028){ref-type="ref"} Decreases in NF‐L were observed following therapeutic interventions in multiple sclerosis, spinal muscular atrophy, and HIV, and following recovery from head injury.[16](#acn350942-bib-0016){ref-type="ref"}, [21](#acn350942-bib-0021){ref-type="ref"}, [29](#acn350942-bib-0029){ref-type="ref"}, [30](#acn350942-bib-0030){ref-type="ref"}, [31](#acn350942-bib-0031){ref-type="ref"}, [32](#acn350942-bib-0032){ref-type="ref"}, [33](#acn350942-bib-0033){ref-type="ref"}, [34](#acn350942-bib-0034){ref-type="ref"} In several neurological conditions, NF‐L levels in CSF and serum or plasma were correlated.[16](#acn350942-bib-0016){ref-type="ref"}, [19](#acn350942-bib-0019){ref-type="ref"}, [20](#acn350942-bib-0020){ref-type="ref"}, [21](#acn350942-bib-0021){ref-type="ref"}, [23](#acn350942-bib-0023){ref-type="ref"}, [26](#acn350942-bib-0026){ref-type="ref"}, [31](#acn350942-bib-0031){ref-type="ref"}, [33](#acn350942-bib-0033){ref-type="ref"}, [35](#acn350942-bib-0035){ref-type="ref"}, [36](#acn350942-bib-0036){ref-type="ref"}, [37](#acn350942-bib-0037){ref-type="ref"}, [38](#acn350942-bib-0038){ref-type="ref"} Elevated levels of NF‐L in animal models of neurodegeneration,[16](#acn350942-bib-0016){ref-type="ref"}, [39](#acn350942-bib-0039){ref-type="ref"}, [40](#acn350942-bib-0040){ref-type="ref"} and decreases following treatment in a model of HIV, demonstrate cross‐species translatability of NF‐L as a biomarker of active neurological disease or injury.[41](#acn350942-bib-0041){ref-type="ref"} These studies led us to evaluate whether NF‐L is a disease‐associated biomarker in CLN2 disease.

Methods {#acn350942-sec-0006}
=======

Canine model, cerliponase alfa treatment, and samples {#acn350942-sec-0007}
-----------------------------------------------------

Studies utilizing miniature long‐haired Dachshunds were reviewed and approved by the University of Missouri Animal Care and Use Committee. All studies were conducted in accordance with the United States Public Health Service's Policy on Humane Care and Use of Laboratory Animals. Affected dogs were generated by breeding carriers that were heterozygous for a c.325delC null mutation in *TPP1*. Dogs were genotyped at this locus using an allelic discrimination assay.[42](#acn350942-bib-0042){ref-type="ref"} A total of 11 Dachshund dogs homozygous for the *TPP1* null mutation (*TPP1* ^−*/*−^) and 6 Dachshund dogs heterozygous for the *TPP1* null mutation (*TPP1* ^+/−^) were evaluated. *TPP1*‐deficient dogs included in this study were treated with intraocular cerliponase alfa by intravitreal injection, and plasma samples were collected at four timepoints between 89 and 251 days. TPP1 activity is not expected outside of the eye based on negligible systemic distribution after intravitreal injection, which is typical for large molecule protein therapeutics.[43](#acn350942-bib-0043){ref-type="ref"} Control plasma samples from 27 Beagles aged 3--24 months were purchased from BioIVT (NY, USA); control samples were collected at an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)‐accredited facility that has Institutional Animal Care and Use Committee oversight.

Clinical trial subjects and samples {#acn350942-sec-0008}
-----------------------------------

Plasma samples from human subjects with CLN2 disease were available from international clinical trials on the safety and efficacy of cerliponase alfa: BMN 190‐201 (NCT01907087), BMN 190‐202 (extension study of BMN 109‐201; NCT02485899), and BMN 190‐203 (NCT02678689), all performed in accordance with the Declaration of Helsinki. Written informed consent was provided by parents or legal guardians and approved by the relevant ethics boards. Details of the subject eligibility criteria have been published elsewhere.[5](#acn350942-bib-0005){ref-type="ref"} A single pretreatment (i.e., baseline) sample was available from 4 subjects; baseline and longitudinally collected samples (from patients with more than 3 months of treatment) were available from 15 subjects; baseline and longitudinally collected samples (from patients with fewer than 3 months of treatment) were available from 2 subjects; longitudinal samples without a baseline measurement were available from 3 subjects. Control plasma samples were obtained from seven unrelated individuals not known to have neurological diseases using the BioIVT resource (<https://www.bioivt.com/>).

NF‐L measurements {#acn350942-sec-0009}
-----------------

Human and cohort 2 samples (dogs 12--17) were stored at −60 to −80°C, centrifuged to remove debris, and analyzed at Quanterix Corporation using a commercially available two‐step digital immunoassay based on single molecule array (Simoa) technology -- the Simoa NF‐light^®^ Advantage assay and Simoa HD‐1 Analyzer (Uman Diagnostics, Umeå, Sweden and Quanterix Corporation, Lexington, MA, USA). Cohort 1 dog samples (dogs 1--11) were tested at BioMarin Pharmaceutical Inc. with the same method that used the Simoa NF‐light^®^ Advantage assay and an HD‐1 Analyzer per manufacturers' instructions. Longitudinal samples and sample groups used for comparison were tested in the same analytical run and were analyzed in duplicate at a four‐fold dilution. Of 80 clinical trial samples available for analysis, data were lost from one replicate in four cases and run in singlicate due to low sample volume in two cases. Data from one control replicate was also lost.

Data processing and analysis {#acn350942-sec-0010}
----------------------------

Some of the patient plasma samples were collected on dates without measurements of CLN2 Clinical Rating scores. To assign CLN2 Clinical Rating scores to each plasma sample, we used scores measured within 7 days from the date of sample collection (first preference) or at the latest date preceding sample collection (second preference).

All statistical analyses were performed using R (version 3.4.1; <https://www.r-project.org/>). Differences between two groups of samples (patients vs. controls for age and baselines vs. controls for NF‐L) were tested by Wilcoxon rank sum tests. Association of baseline NF‐L levels with age was measured by both Spearman's rank and Pearson correlation coefficients. Association of baseline NF‐L levels with CLN2 Clinical Rating scores was measured by Spearman's rank correlation coefficient. Association of patient NF‐L levels in log scale with treatment time was examined by a linear model implemented in the *limma* package in R after adjusting for age at baseline and CLN2 Clinical Rating scores, and treating patients as a random effect.[44](#acn350942-bib-0044){ref-type="ref"}, [45](#acn350942-bib-0045){ref-type="ref"} In the canine model of CLN2 disease, association of NF‐L expression in log scale with age, and association of plasma NF‐L and CSF NF‐L levels in log scale were evaluated using the *limma* package by a linear model adjusted for differences between dogs. A *P*‐value less than 0.05 was considered statistically significant.

Results {#acn350942-sec-0011}
=======

NF‐L in a canine model of CLN2 disease increases with disease progression {#acn350942-sec-0012}
-------------------------------------------------------------------------

In a cohort of five affected (*TPP1* ^−*/*−^) Dachshunds and six age‐matched carrier (*TPP1* ^+/−^) Dachshunds (cohort 1), NF‐L levels started to increase around 4 months of age (Fig. [1](#acn350942-fig-0001){ref-type="fig"}A). In a second, slightly older cohort of six *TPP1* ^−*/*−^ Dachshunds progressing through the symptomatic stages of neurodegeneration (cohort 2), increases in plasma NF‐L levels were also observed in each animal, rising to more than ten times initial levels as the animals approached end stage disease (Fig. [1](#acn350942-fig-0001){ref-type="fig"}B). In cohort 1, the rate of increase in NF‐L levels was significantly more rapid in affected dogs (doubling time of 52 days) than in carrier dogs (doubling time of 204 days) (*P* \< 0.001); the rate of increase in affected dogs in cohort 2 (doubling time of 48 days) was similar to cohort 1. In contrast, almost all plasma samples from control dogs (Beagles, *N* = 27) at 3--24 months of age showed minimal change in NF‐L levels throughout this period, similar to levels seen in *TPP1* ^+/−^ Dachshunds and *TPP1* ^−*/*−^ Dachshunds at the very start of neuropathology (approximately 2 months of age when ventricular volume increases have been noted) (Fig. [1](#acn350942-fig-0001){ref-type="fig"}C).[6](#acn350942-bib-0006){ref-type="ref"} We note that the carrier Dachshunds display a larger age‐dependent increase in NF‐L than is seen in the *TPP1* ^+/+^ Beagles; however, we cannot unequivocally ascribe that difference to the different *TPP1* genotype versus breed, housing, or other variables. *TPP1* ^+/−^ Dachshunds are phenotypically normal, showing no signs of neurological disease and having lifespans that are typical for healthy dogs of this breed.[46](#acn350942-bib-0046){ref-type="ref"}

![NF‐L levels increase in plasma samples from a canine model of CLN2 disease. (A) NF‐L levels are shown using a log~10~ scale on the *Y*‐axis and age on the *X*‐axis. NF‐L levels increase more rapidly in affected animals (*TPP1* ^−*/*−^ Dachshunds, *N* = 5, orange lines) than in carriers (*TPP1* ^+/−^ Dachshunds, *N* = 6, blue lines). Animal IDs are annotated. Four of the affected dogs (IDs 1, 2, 3, and 4) were treated with intraocular cerliponase alfa by intravitreal injection. Color bars on top represent different disease stages: no symptoms (0--60 days, green), ventricular volume change (61--210 days, yellow), failure to complete T‐maze (211--280 days, orange), and death (281--329 days, red).[6](#acn350942-bib-0006){ref-type="ref"} (B) NF‐L levels are shown using a log~10~ scale on the *Y*‐axis and age on the *X*‐axis. NF‐L levels increase with progressive symptoms in a second group of *TPP1* ^−*/*−^ animals treated with intraocular cerliponase alfa by intravitreal injection (Dachshunds, *N* = 6). Color bars on top represent disease stages as in (A). (C) NF‐L levels are shown using a log~10~ scale on the *Y*‐axis and age on the *X*‐axis. In healthy animals (*TPP1* ^+/+^ Beagles, *N* = 27), NF‐L levels are not associated with age (*P* = 0.18). However, if the two outliers with the highest NF‐L levels are excluded, the best fit regression line of NF‐L levels increased by only 63% from 90 days to 720 days (*P* \< 0.001). Boxes indicate the interquartile range (IQR), and the median is shown using an additional horizontal line. Whiskers extend up to the furthest data point within 1.5 times the IQR.](ACN3-6-2437-g001){#acn350942-fig-0001}

At a subset of the plasma collection time points, CSF was also collected from the first cohort of Dachshunds; NF‐L levels were measured in those paired CSF samples. While the absolute levels of NF‐L were consistently higher in CSF compared to plasma at any given age in affected samples and carriers, the levels in plasma correlated to the levels in CSF (*P* = 0.021) (Fig. [2](#acn350942-fig-0002){ref-type="fig"}).

![Positive correlation between plasma NF‐L and CSF NF‐L levels in a canine model of CLN2 disease. NF‐L levels in plasma are shown using a log~10~ scale on the *Y*‐axis and NF‐L levels in matched CSF are shown using a log~2~ scale on the *X*‐axis. A subset of the time points from Figure [1](#acn350942-fig-0001){ref-type="fig"} that had matched plasma and CSF NF‐L measurements are plotted. Animal IDs are annotated. In the affected animals (orange lines), plasma NF‐L level increased by 56% (*P* = 0.021) if CSF NF‐L level increased by 100%. Carriers are shown as blue lines or triangles.](ACN3-6-2437-g002){#acn350942-fig-0002}

Patient characteristics {#acn350942-sec-0013}
-----------------------

Plasma samples were obtained from subjects with CLN2 disease who were enrolled in clinical trials of cerliponase alfa (TPP1 ERT) and from individuals not known to have neurological diseases. Patient characteristics are shown in Tables [1](#acn350942-tbl-0001){ref-type="table"} and [2](#acn350942-tbl-0002){ref-type="table"}. The median age of the control individuals was older than the median age of CLN2 disease subjects by 4.7 years at baseline (Wilcoxon rank sum test, *P* \< 0.001). ERT was administered to all CLN2 disease subjects via ICV device, which had been placed 3--15 days (median = 8 days and mean = 10 days) before baseline[5](#acn350942-bib-0005){ref-type="ref"} *.*

###### 

Patient characteristics -- all subjects and controls.

  Population                                                             CLN2 disease (*N* = 24)                                          Controls (*N* = 7)
  ---------------------------------------------------------------------- ---------------------------------------------------------------- --------------------
  Median age at baseline (years)                                         4.28 (*n* = 21[\*](#acn350942-note-0002){ref-type="fn"})         9
  Baseline age range (years)                                             1.72--6.85 (*n* = 21[\*](#acn350942-note-0002){ref-type="fn"})   8--11
  Sex                                                                    15 F, 9 M                                                        7 M
  Median CLN2 disease rating scale score (combined motor and language)   3                                                                NA

Three patients did not provide baseline samples.

John Wiley & Sons, Ltd

###### 

CLN2 disease patient subsets.

  Population                                                                      Baseline sample only (*n* = 4)   Baseline and longitudinal samples, ≥3 months of treatment (*n* = 15)   Baseline and longitudinal samples, \<3 months of treatment (*n* = 2)   Longitudinal samples with no baseline measurement (*n* = 3)
  ------------------------------------------------------------------------------- -------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------
  Median age at baseline (years)                                                  3.89                             4.35                                                                   3.68                                                                   3.03
  Baseline age range (years)                                                      1.72--4.81                       3.10--6.85                                                             2.88--4.48                                                             2.98--4.28
  Sex                                                                             2 F, 2 M                         9 F, 6 M                                                               2 F                                                                    2 F, 1 M
  Baseline median CLN2 disease rating scale score (combined motor and language)   4                                3                                                                      4.5                                                                    6

John Wiley & Sons, Ltd

NF‐L is increased in CLN2 disease subjects at baseline {#acn350942-sec-0014}
------------------------------------------------------

Plasma samples were analyzed for NF‐L at baseline and throughout the course of cerliponase alfa treatment. At baseline, NF‐L levels in subjects (*N* = 21) were 48‐fold higher than those in control samples (*N* = 7); median (interquartile range \[IQR\]) = 153.2 pg/mL (118.7--183.4) in subjects versus 3.21 pg/mL (2.75--4.23) in controls (Wilcoxon rank sum test, *P* \< 0.001) (Fig. [3](#acn350942-fig-0003){ref-type="fig"}). All CLN2 disease subjects had higher NF­L concentrations than any of the controls, with the lowest baseline value in a CLN2 disease subject (79.83 pg/mL) being over 14‐fold higher than the highest control value (5.52 pg/mL).

![NF‐L levels in plasma samples from CLN2 disease patients at baseline and control individuals. Box plots of NF‐L levels in two groups are displayed using a log~10~ scale on the *Y*‐axis. NF‐L levels are significantly increased in patients (*N* = 21, range 79.83--388.09) compared with controls (*N* = 7, range 2.08--5.52) (Wilcoxon rank sum test, *P* = 1.7 × 10^−6^). NF‐L levels are shown using a log~10~ scale, with boxes indicating the interquartile range (IQR), and the median shown using an additional horizontal line. Whiskers extend up to the furthest datapoint within 1.5 times the IQR.](ACN3-6-2437-g003){#acn350942-fig-0003}

NF‐L is not associated with age or symptom severity at baseline {#acn350942-sec-0015}
---------------------------------------------------------------

To determine if, within the patient population, baseline NF‐L levels are associated with severity of neuropathology and symptoms, or with age, we examined associations between baseline NF­L, age, and CLN2 Clinical Rating scores (Fig. [4](#acn350942-fig-0004){ref-type="fig"}A and B). No associations were found with either age (*N* = 21, Pearson's correlation coefficient = 0.08, *P* = 0.73; Spearman's correlation coefficient = 0.22, *P* = 0.33) or combined baseline motor and language scores (*N* = 21, Spearman's correlation coefficient = −0.02, *P* = 0.95). NF‐L levels were variable across both ages and CLN2 Clinical Rating scores, with the highest levels found in subjects in the middle of the age group studied and subjects scoring in the middle of the rating scale. Subjects with low scores, and therefore more severe disease, did not consistently have the highest NF‐L levels.

![Baseline plasma NF‐L levels are not associated with age (A) or motor and language scores (B). The linear regression line is plotted on the graphs with NF‐L levels on the *Y*‐axis and age or CLN2 score on the *X*‐axis. (A) Baseline NF‐L levels show high variability with age at baseline (*N* = 21), with the highest levels found in patients in the middle of the age group studied. (B) Baseline NF‐L levels are also variable for each CLN2 Clinical Rating motor + language score group at baseline (*N* = 21), with the highest levels found in patients in the middle of the range.](ACN3-6-2437-g004){#acn350942-fig-0004}

NF‐L decreases in CLN2 disease patients following cerliponase alfa treatment {#acn350942-sec-0016}
----------------------------------------------------------------------------

To examine the effect of cerliponase alfa on neuropathology, NF‐L levels were measured in longitudinal plasma samples from 18 clinical trial subjects who had samples collected after at least 3 months of treatment. These patients provided between two and seven samples, with a median time on treatment of 33 months (range = 11--43 months). NF­L levels decreased during treatment by about 50% each year compared with the previous year (95% CI: 46.1%--53.8%; *P* \< 0.001) (Fig. [5](#acn350942-fig-0005){ref-type="fig"}). While NF­L did temporarily increase at some time points for five subjects, overall NF‐L levels continued to decrease over the course of treatment for all subjects.

![Plasma NF‐L levels decrease during cerliponase alfa treatment in CLN2 disease patients. NF‐L levels are shown using a log~10~ scale on the *Y*‐axis and time on treatment on the *X*‐axis. Samples were provided over a period of up to almost 4 years (*N* = 18). Levels decreased by 49.8% annually (95% CI: 46.1%--53.8%; *P* \< 0.001) and are not associated with age at baseline (*P* = 0.26) or CLN2 Clinical Rating scores (*P* = 0.83)*.* The grey area indicates the range of NF‐L expression in control samples. Each patient is represented by a different color.](ACN3-6-2437-g005){#acn350942-fig-0005}

Five subjects experienced a total of eight episodes of increased NF‐L above previous levels during the first 6 months (numbers 23 and 27) and later in the course of treatment with cerliponase alfa (numbers 10, 11, 19, and 23). In four of these eight episodes, seizure activity was reported in the 2 weeks prior to collection of the sample with increased NF‐L. However, in the same set of subjects, there were four other seizure activity periods reported, after which NF‐L levels were decreased compared with the previous sampling. None of the episodes of increased NF‐L level above previous levels was associated with concurrent cerliponase alfa dose interruption.

Discussion {#acn350942-sec-0017}
==========

This study is the first to examine a biochemical biomarker of treatment response in patients with CLN2 disease and is the first to examine NF‐L in a pediatric population with a lysosomal storage disorder. The *TPP1* ^−*/*−^ dogs provided an opportunity to follow NF‐L during the natural course of disease development. In addition, the absence of allelic heterogeneity of the *TPP1* locus (as found in humans), the comparatively homogeneous genetic background of the animal model, and the consistent environment reduce variability in the course of the canine disease compared with the range seen in children. We demonstrated post‐disease onset increases in NF‐L in the canine disease model, and while there are species‐specific differences in absolute levels of plasma NF‐L (\<5 pg/mL in control human samples versus \>50 pg/mL in CLN2 disease patients, versus \<20 pg/mL in control dogs versus \>100 pg/mL after disease progression in *TPP1* ^−*/*−^ dogs), markedly elevated circulating NF‐L is a common feature in CLN2 disease across the two species. The pre‐treatment levels observed in CLN2 disease patients is at the high end of neurological disease levels -- similar to that seen in amyotrophic lateral sclerosis, and higher than many other neurodegenerative diseases.[16](#acn350942-bib-0016){ref-type="ref"}, [19](#acn350942-bib-0019){ref-type="ref"}, [20](#acn350942-bib-0020){ref-type="ref"}, [21](#acn350942-bib-0021){ref-type="ref"}, [23](#acn350942-bib-0023){ref-type="ref"}, [24](#acn350942-bib-0024){ref-type="ref"}, [26](#acn350942-bib-0026){ref-type="ref"}, [27](#acn350942-bib-0027){ref-type="ref"}, [28](#acn350942-bib-0028){ref-type="ref"}, [31](#acn350942-bib-0031){ref-type="ref"}

The canine *TPP1* ^−*/*−^ model shows lysosomal storage body accumulation and follows a predictable and well‐characterized disease progression, with clinical signs similar to those in children with CLN2 disease, including seizures, ataxia, and visual deficits.[6](#acn350942-bib-0006){ref-type="ref"}, [42](#acn350942-bib-0042){ref-type="ref"}, [47](#acn350942-bib-0047){ref-type="ref"} The animals reach end‐stage disease status at approximately 44 weeks of age and disease progression can be ameliorated with CNS ERT,[6](#acn350942-bib-0006){ref-type="ref"} recapitulating the CLN2 disease patient phenotype. In this predictable genetic disease setting, mild NF‐L increases were observed beginning a few weeks after ventricular volume changes are usually observed, then progressing to 100 pg/mL or higher during or before the time at which overt cognitive defects usually occurred. While successive samples from the same animal almost always showed an increase in NF‐L, there was some variability (greater than twofold) across affected animals of the same age. Baseline samples from CLN2 disease individuals in the cerliponase alfa study (age range: 1.7--6.9 years) all showed NF‐L to be elevated by at least 14‐fold relative to the highest level in a control individual; again, NF‐L levels also showed considerable differences between individuals.

It should be noted that while no significant relationships between NF‐L and age, nor NF‐L and disease severity, were detected in the CLN2 disease patients studied, those relationships may not be evident in this study because the available human samples were from subjects concentrated in limited age and clinical score ranges. It is possible that investigation of more samples from younger, presymptomatic patients would reveal a progressive increase similar to that seen in the canine model. The observation of elevated NF‐L in those subjects with CLN2 Clinical Rating Scale motor‐language scores of 6, who have not yet suffered major declines in either motor or language function, suggests neuropathological activity similar to that in patients beginning to show decreases in CLN2 motor‐language scores. Though longitudinal samples from untreated CLN2 disease patients were unavailable, the range of elevated NF‐L levels in these samples is consistent with the results from the canine model of the disease where NF‐L consistently rises during disease progression. It should be noted that CLN2 subjects all had an ICV device surgically placed; device placement surgery has previously been shown to result in a small and temporary increase in NF‐L levels.[48](#acn350942-bib-0048){ref-type="ref"} While some of the elevated levels may be the result of the device placement, the absolute level of NF‐L at baseline, the kinetics of NF‐L decline, and the similar observation of elevated NF‐L in the canine model (which were not catheterized) support the conclusion that NF‐L is a marker of CLN2 disease and treatment response.

Importantly, NF‐L levels decreased by approximately 50% annually during treatment with cerliponase alfa, with all subjects displaying decreases over the time period examined. In several subjects, levels decreased almost to those found in our control population. The repeated measurement of NF‐L levels over a 1‐ to 4‐year treatment period provides insight into the time course and consistency of the NF‐L response. The observation that NF‐L levels displayed a yearly, first‐order logarithmic decline (approximately 50% decline compared with the previous year), leads us to speculate that the underlying neuropathological disease progression is continuing to decrease over time with ongoing treatment.

In 5 out of 18 subjects, small and rare increases in NF‐L were noted at one or two time points, totaling eight NF‐L elevations out of the 57 total intervals tested across all individuals (Fig. [5](#acn350942-fig-0005){ref-type="fig"}). The rare instances where NF‐L increased during a sampling interval were anomalies for which we were unable to identify a causal event or any association with disease activity. The frequency of sample collection does not permit discrimination between rises occurring on a time course of days or weeks. Neurological adverse events reported prior to increased NF‐L were seizures, which are a hallmark of CLN2 disease. Although seizures sometimes occurred prior to NF‐L increases (four out of eight episodes), there were just as many instances where seizures did not result in NF‐L increase; while we cannot rule out that some seizures did result in NF‐L increases, these observations suggest that seizures are unlikely to be the principal event inciting NF‐L increase. The few instances of increases in NF‐L levels were not explained by concurrent interruptions in dosing with cerliponase alfa.

In addition to its structural role in axons, NF‐L plays a role in neuronal repair.[17](#acn350942-bib-0017){ref-type="ref"}, [49](#acn350942-bib-0049){ref-type="ref"} How its role in repair is reflected in the levels of NF‐L in blood is not well understood. Interestingly, Lang et al. found NF‐L protein levels declined dramatically immediately after injury to mouse sciatic nerves, followed by increased NF‐L protein synthesis by Day 7 postinjury.[50](#acn350942-bib-0050){ref-type="ref"} In a similar rat experiment, *Nefl* mRNA levels declined immediately following injury but rebounded during the late stage of neuronal recovery.[51](#acn350942-bib-0051){ref-type="ref"} In people who experienced traumatic head injury, the damage‐associated molecular pattern factor S100B was elevated almost immediately after injury, while serum NF‐L levels rose more gradually over time with a more extended recovery timeline than S100B to baseline levels.[52](#acn350942-bib-0052){ref-type="ref"} In our canine data, NF‐L levels began to rise after the time when initial ventricular volume increases were noted. These observations are consistent with NF‐L release being associated with active neuronal degeneration as well as possible repair mechanisms. Similarly, high baseline levels of NF‐L in CLN2 disease subjects could be the result of NF‐L being "leaked" from damaged neurons or released as a result of contemporaneous repair mechanisms. The kinetics of NF‐L turnover are likely to be complex and may include both damage‐induced release and repair mechanisms. Furthermore, how NF‐L moves from CSF to the blood, and how it is turned over in the blood, are not fully understood, which adds another layer of complexity in interpreting individual‐to‐individual variation in plasma NF‐L levels, as well as imperfect tracking of the concentration of NF‐L in plasma and CSF. Finally, TPP1 deficiency may also result in NF‐L release from peripheral neurons, which may contribute to the elevated levels observed in the blood.

To our knowledge, this study is the first to describe NF‐L as a treatment‐responsive biomarker of neuronal pathology in a pediatric lysosomal storage disease. NF‐L may provide clinicians with a tool to objectively follow the effect of treatment with cerliponase alfa in CLN2 disease and disease‐modifying therapy in other lysosomal storage diseases with neuropathology. Further study is warranted to confirm NF‐L as a disease biomarker that responds to treatment and to evaluate the role of NF‐L as a biomarker that may inform the timing of treatment initiation.
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